# OnCo record disease-volume-chaarted (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/disease-volume-chaarted/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "disease-volume-chaarted" ;
  schema:name "Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk"@en ;
  schema:alternateName "CHAARTED criteria"@en, "high-volume disease"@en, "low-volume disease"@en, "high-volume mHSPC"@en, "low-volume mHSPC"@en, "LATITUDE criteria"@en, "LATITUDE high risk"@en, "high-risk mHSPC"@en, "oligometastatic prostate cancer"@en, "de novo metastatic prostate cancer"@en, "synchronous versus metachronous metastases"@en, "metastatic burden"@en ;
  schema:description "In newly metastatic hormone-sensitive prostate cancer the treatment plan starts with a count: four or more bone metastases with at least one outside the spine and pelvis, or any spread to liver or lung, is high-volume disease (CHAARTED), and high-volume men gain years from adding docetaxel to hormone therapy while low-volume men gain more from radiotherapy to the prostate."@en ;
  schema:url <https://onco.cc/terms/disease-volume-chaarted/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/terms/mcrpc-mhspc/>, <https://onco.cc/terms/adt/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/terms/radiotherapy/> ;
  onco:cancers <https://onco.cc/cancers/prostate-mhspc/> .